Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award
The Lancet reports that in patients with resistant hypertension, aprocitentan was well-tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40Upon approval
Ad hoc announcement pursuant to Art. 53 LR Idorsia announces financial results for the first nine months of 2022 - QUVIVIQ becoming a global brand Allschwil, Switzerland - October 25, 2022Idorsia
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland – October 25, 2022Idorsia Ltd (SIX: IDIA) today announced its financial results for the.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - July 26, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2022. Commercial highlights QUVIVIQ